Inhaled corticosteroid use by exacerbations and eosinophils: a real-world COPD population

Figures & data

Table 1 Baseline characteristics of all EU patients with derived GOLD classification (n=1,528)

Parameter	Total (n=1,528)	GOLD A (n=183)	GOLD B (n=935)	GOLD C (n=13)	GOLD D (n=397)
Mean age, mean	65.7	61.7	65.8	65.3	67.4
Male/female, %	68.2/31.8	73.8/26.2	65.0/35.0	92.3/7.7	72.3/27.7
Mean body mass index, kg/m^2	26.7	26.7	26.6	27.1	26.9
Current smokers, %	30.2	23.2	29.3	9.1	36.2
Pack years ≥10, % of current smokers	95.1	92.7	95.6	100.0	94.7
Ex-smokers, %	62.5	71.3	62.1	90.9	58.4
Pack years ≥10, % of ex-smokers	97.7	95.2	98.2	100.0	97.7
Employment status, %
Retired  working full time	63.5 18.0	53.7 30.5	60.3 19.5	84.6 15.4	74.8 9.2
Homemaker	9.4	9.6	11.3	0.0	5.3
Unemployed	6.0	3.4	5.6	0.0	8.4
Working part time	2.9	2.8	3.2	0.0	2.3
Current comorbidities, %^a
Hypertension	67.2	53.9	66.0	58.3	76.5
Elevated cholesterol/hyperlipidemia	28.9	26.1	25.6	33.3	37.5
Diabetes	15.3	13.3	13.3	58.3	19.6
Anxiety	13.6	6.1	11.8	0.0	21.7
Gastroesophageal reflux disease (GERD)	10.9	6.1	10.6	0.0	14.0
Mean time since diagnosis, months	62.2	38.6	57.9	40.6	84.5
Mean CAT score	20.2	5.8	20.9	7.1	25.7
mMRC score
0–1	59.6	95.1	62.3	53.8	36.4
2–4	40.4	4.9	37.7	46.2	63.6
Mean post-bronchodilator FEV1 (% predicted)	64.6	74.7	66.5	61.0	56.6
Mean post-bronchodilator FEV1/FVC	0.58	0.62	0.60	0.53	0.54
Mean frequency of hospitalizations in last 12 months	0.2	0.0	0.0	0.2	0.9

Note: ^aPresent in >10% of the total population.

Abbreviation: CAT, COPD Assessment Test.

Figure 1 Patient disposition.

Abbreviation: CAT, COPD Assessment Test.

Figure 2 The proportions of chronic obstructive pulmonary disease (COPD) patients with a history of 0, 1, 2, or ≥3 exacerbations in the previous 12 months in Global Initiative for COPD (GOLD) groups B and D. *^aExacerbations which required treatment with oral corticosteroids, antibiotic, and/or hospital admission. *^bExacerbations which required hospital admission. Population: All EU COPD-only patients with a derived GOLD group (calculated by using physician-reported recent history of exacerbations and patient-reported CAT score).

Abbreviation: CAT, COPD Assessment Test.

Figure 3 The proportions of chronic obstructive pulmonary disease patients with histories of 0, 1, or ≥2 of total and severe exacerbations by eosinophil blood count distribution. *^aExacerbations which required treatment with OCS, antibiotic, and/or hospital admission. *^bExacerbations which required hospital admission. Population: All EU COPD-only patients with a derived GOLD group (calculated by using physician-reported recent history of exacerbations and patient-reported CAT score) and a stated eosinophil blood count.

Abbreviation: CAT, COPD Assessment Test.

Figure 4 Current treatment patterns by Global Initiative for Chronic Obstructive Pulmonary Disease (GOLD) group. Population: All EU COPD-only patients with a derived GOLD group (calculated by using physician-reported recent history of exacerbations and patient-reported CAT score).

Abbreviation: CAT, COPD Assessment Test.

Figure 5 The percentages of patients receiving inhaled corticosteroid treatment by exacerbation rate and by eosinophil blood count. Population: All EU COPD-only patients with a stated eosinophil blood count and known recent history of exacerbations.